Investment
Features
FeesSafety
Academy
More
Pluang+

Everpure joins S&P 500, marking a milestone in its growth and AI-ready data management.

Market News
08 Sep 2026
PRNewsWire
View Source
Bullish
Everpure joins S&P 500, marking a milestone in its growth and AI-ready data management.

Everpure, a leader in storage and data management, will join the S&P 500 index on September 21, 2026. This inclusion reflects the company's strong financial performance and market confidence in its strategy as businesses prepare their data for AI applications. Everpure's platform helps organizations manage data efficiently while reducing energy use, positioning it well for future growth in the AI era.

More News

GameStop beats Q2 revenue estimates with strong collectibles growth despite overall sales decline.

GameStop beats Q2 revenue estimates with strong collectibles growth despite overall sales decline.

GameStop reported Q2 2026 revenue of $790.20 million, beating analyst estimates but showing a 19% year-over-year decline due to a strong prior year and strategic store closures. The company's Collectibles segment grew 57% to $356.30 million, offsetti...

Company Fundamentals
Bullish
2 hours ago
Raymond James sets Dyne Therapeutics price target at $37, signaling 80% upside on clinical progress.

Raymond James sets Dyne Therapeutics price target at $37, signaling 80% upside on clinical progress.

Raymond James analyst Michael Freeman raised Dyne Therapeutics' price target to $37, suggesting an 80.75% upside from its current price around $20.60. The clinical-stage biotech is advancing treatments for muscle diseases like Myotonic Dystrophy Type...

Analyst Insights
Bullish
2 hours ago
17EdTech to report Q3 earnings with expected loss but strong financial health and $10M buyback plan

17EdTech to report Q3 earnings with expected loss but strong financial health and $10M buyback plan

17 Education & Technology Group Inc. (17EdTech) will release its Q3 earnings on September 8, 2026, with analysts forecasting a loss of $8.60 per share and revenue of $73.47 million. Despite ongoing unprofitability, the company maintains strong financ...

Company Fundamentals
Neutral
3 hours ago
Roivant Sciences price target jumps 24.7% after strong Phase 2 trial for lung disease drug

Roivant Sciences price target jumps 24.7% after strong Phase 2 trial for lung disease drug

Roivant Sciences saw its price target raised to $52 by Jefferies, reflecting a 24.7% potential gain, following positive Phase 2 trial results for mosliciguat, a drug treating pulmonary hypertension linked to interstitial lung disease. The trial showe...

Analyst Insights
Bullish
3 hours ago
EVI Industries posts strong Q4 revenue of $121.87M and 15% annual growth to $446.6M.

EVI Industries posts strong Q4 revenue of $121.87M and 15% annual growth to $446.6M.

EVI Industries reported Q4 revenue of $121.87 million, surpassing analyst expectations of $117.1 million, and achieved a record fiscal year revenue of $446.6 million, marking a 15% increase year-over-year. The company met earnings per share forecasts...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App